- Home
- SCKT vs CANF Comparison
SCKT vs CANF Comparison
Compare SCKT & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCKT
- CANF
- Stock Information
- Founded
- SCKT 1992
- CANF 1994
- Country
- SCKT United States
- CANF Israel
- Employees
- SCKT N/A
- CANF N/A
- Industry
- SCKT Computer Manufacturing
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- SCKT Technology
- CANF Health Care
- Exchange
- SCKT Nasdaq
- CANF Nasdaq
- Market Cap
- SCKT 8.4M
- CANF 9.6M
- IPO Year
- SCKT 1995
- CANF N/A
- Fundamental
- Price
- SCKT $1.02
- CANF $0.59
- Analyst Decision
- SCKT
- CANF Strong Buy
- Analyst Count
- SCKT 0
- CANF 2
- Target Price
- SCKT N/A
- CANF $14.50
- AVG Volume (30 Days)
- SCKT 14.2K
- CANF 174.9K
- Earning Date
- SCKT 10-23-2025
- CANF 11-27-2025
- Dividend Yield
- SCKT N/A
- CANF N/A
- EPS Growth
- SCKT N/A
- CANF N/A
- EPS
- SCKT N/A
- CANF N/A
- Revenue
- SCKT $16,710,984.00
- CANF $560,000.00
- Revenue This Year
- SCKT $8.62
- CANF $461.72
- Revenue Next Year
- SCKT N/A
- CANF N/A
- P/E Ratio
- SCKT N/A
- CANF N/A
- Revenue Growth
- SCKT N/A
- CANF N/A
- 52 Week Low
- SCKT $0.85
- CANF $0.59
- 52 Week High
- SCKT $1.72
- CANF $3.12
- Technical
- Relative Strength Index (RSI)
- SCKT 46.41
- CANF 32.24
- Support Level
- SCKT $1.01
- CANF $0.60
- Resistance Level
- SCKT $1.04
- CANF $0.64
- Average True Range (ATR)
- SCKT 0.02
- CANF 0.03
- MACD
- SCKT -0.00
- CANF 0.00
- Stochastic Oscillator
- SCKT 29.82
- CANF 2.03
About SCKT Socket Mobile Inc.
Socket Mobile Inc is a producer of data capture products. The company's products are integrated into mobile applications used in mobile point of sale (mPOS), commercial services (field workers), asset tracking, manufacturing process and quality control, transportation and logistics (goods tracking and movement), event management (ticketing, entry, access control, and identification), medical and education. The company offers barcode scanning products for both one-dimensional, including imager and laser, and two-dimensional barcode scanning in standard and durable cases. The company's geographical segments are the Americas, Europe, Asia Pacific, and Africa, of which the majority of the revenue is generated from the United States.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).